吉西他滨联合长春瑞宾治疗晚期非小细胞肺癌的疗效和安全性观察  

The Clinical Study on the efficacy and safety of gemcitabine combined with vinorelbine in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：刘晓燕[1] 邹青峰[1] 陈文晟[1] 马磊[1] 胡晓晔[1] 李志彪[1] 

机构地区：[1]广州医学院附属肿瘤医院内三科,510095

出　　处：《大家健康（学术版）》2012年第14期11-13,共3页

摘　　要：目的探讨吉西他滨联合长春瑞宾治疗复治晚期非小细胞肺癌的疗效及安全性。方法 20例复治的Ⅳ期非小细胞肺癌患者接受吉西他滨联合长春瑞宾的化疗,方案:吉西他滨1g/m2,静脉推注,第1、8天,长春瑞宾25mg/m2,第1、8天,静脉推注,每3周一次。结果 20例患者中PR4例,SD9例,PD7例,有效率(CR+PR)为20%。主要的化疗反应为骨髓抑制、胃肠道反应,所有患者均能耐受。结论吉西他滨联合长春瑞宾治疗复治晚期非小细胞肺癌有效,不良反应较小,患者更容易耐受。Objective To observe the efficacy and toxicity of gemcitabine combined with vinorelbine for patients with non-small cell lung cancer(NSCLC). Methods 20 patients of refractory non-small cell lung cancer receiving gemcitabine plus Vinorelbine chemotherapy,gemcitabine 1g / m2, IV, first,8 days,vinorelbine 25mg / m2, first,8 days,IV,Repeated every 3 weeks. Results 20 patients with PR 4 cases,SD 9 cases,PD 7 cases,the total efficiency ( CR+PR ) was 20%. The main response to chemotherapy myelosuppression,gastrointestinal reactions, all patients were able to tolerate. Conclusion:the combination of gemcitabine and vinorelbine in treatment of refractory non small cell lung cancer patients is effective with lower toxicity.

关 键 词：非小细胞肺癌 长春瑞宾 吉西他滨 

分 类 号：R734.2[医药卫生—肿瘤]